PSMA PET/CT 在新诊断的不利中危前列腺癌患者中的适用性 - 基于肿瘤体积的风险分层。
The appropriateness of PSMA PET/CT in newly diagnosed unfavorable intermediate-risk prostate cancer patients-towards a tumor volume-based risk stratification.
发表日期：2024 Sep 23
作者：
Marinus J Hagens, Wietske I Luining, Liselotte M S Boevé, Remco J J Knol, Ton A Roeleveld, Sandra Srbljin, Saskia Weltings, Jose C C Koppes, Daniela E Oprea-Lager, André N Vis, Pim J van Leeuwen, Henk G van der Poel
来源：
PROSTATE CANCER AND PROSTATIC DISEASES
摘要：
本研究重新评估了 PSMA PET/CT 对不利的中危前列腺癌 (PCa) 的诊断价值，并验证了荷兰前列腺癌网络 (PCNN) 的亚分类。对接受 PSMA PET/CT 的男性进行了分析，评估了转移性疾病的发生率及其与 PCNN 亚组的相关性。12.4% 的患者发现转移性疾病。较高的 PCNN 亚组与增加的转移潜力相关；低转移潜能病例的几率显着较低（OR：0.19，95% CI 0.06-0.62；p = 0.01）。我们的研究结果重申了 PSMA PET/CT 对不利的中危 PCa 的诊断价值，并验证了 PCNN 亚分类，减少了扫描负担48.1%。© 2024。作者，获得施普林格自然有限公司的独家许可。
This study reassesses the diagnostic value of PSMA PET/CT in unfavorable intermediate-risk prostate cancer (PCa) and validates the Prostate Cancer Network the Netherlands (PCNN) subclassification.Men subjected to PSMA PET/CT were analyzed, evaluating the incidence of metastatic disease and its correlation with PCNN subgroups.Metastatic disease was identified in 12.4% of patients. Higher PCNN subgroups correlated with increased metastatic potential; odds were significantly lower in low metastatic potential cases (OR: 0.19, 95% CI 0.06-0.62; p = 0.01).Our findings reaffirm PSMA PET/CT's diagnostic value in unfavorable intermediate-risk PCa and validate the PCNN subclassification, reducing scan burden by 48.1%.© 2024. The Author(s), under exclusive licence to Springer Nature Limited.